📉 The Financial Deep Dive
Okay, toh P&G Health Limited (PGHL) ne apna Q3 results nikala hai jo December 31, 2025 ko end hua. Sabse badi baat, inki revenue mein 21% ka zabardast jump aaya hai, total ₹368 crore pahunch gaya. Yeh growth mili hai unke naye products ki wajah se, jaise ki Livogen Iron Gummies aur Neurobion Nerve Pain Relief Cream, aur unki supply chain bhi kaafi smooth chal rahi hai. Company ka Profit After Tax (PAT) is quarter mein ₹78 crore raha.
🎤 Management Commentary
MD Mr. Milind Thatte ne bataya ki company ka focus consumers ki needs ko samajhna hai. Yeh log bade brands banane, sahi tarike se market mein pahunchne aur science-based innovations par focus kar rahe hain. Goal hai ki apne trusted brands ke through sustainable growth aur value creation karein.
💰 Dividend Action
Shareholders ke liye ek aur achhi khabar hai! PGHL ne ₹160 per equity share ka interim dividend declare kiya hai FY 2025-26 ke liye. Isme ₹50 ka special dividend bhi included hai. Isse company ka confidence dikhta hai aur shareholders ko reward karne ka commitment bhi.
🚩 Risks & Outlook
Abhi tak company ne aage ke liye koi specific financial guidance nahi di hai, na hi balance sheet ya cash flow ke baare mein detailed jankari share ki hai. Toh future mein kya hone wala hai, iska exact idea lagana investors ke liye thoda mushkil hai. Naye products aur supply chain improvements par reliance hai, toh agar execution mein dikkat aayi toh performance par asar pad sakta hai. Zyada details ke liye investors ko future updates ka wait karna hoga.